Adial Pharmaceuticals
Charlottesville, Virginia, United States · Biotechnology, Healthcare, Health Care
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Comp
Key facts
- Headquarters
- Charlottesville, Virginia, United States
- Employees
- 17
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (ADIL)
- Website
- adial.com
- Company page
Recent activity at Adial Pharmaceuticals
- : SEC 8-K (5.02): On September 17, 2026, Adial Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders where significant changes were approved by the stockholders. These include Amendment No. 8 to the 2017 Equity Incentive Plan, increasing the shares available for issuance, the adoption of the 2026 Equity Incentive Plan, and the establishment of the 2026 Employee Stock Purchase Plan. These actions could impact stockholder incentives and overall employee compensation structures, indicating a strategic move to enhance company performance and employee engagement.
- : Adial Pharmaceuticals Appoints Matthew Davidson as President and CEO
- : SEC 8-K (5.01): On August 18, 2026, Adial Pharmaceuticals, Inc. received a delisting notice from Nasdaq due to failure to meet the minimum stockholders' equity requirement of $2,500,000, as reported in their recent Form 10-Q. The notice indicates that the company also fails to meet the alternative standards of having a market value of listed securities above $35 million or net income from continued operations of $500,000. This situation potentially indicates a significant financial challenge for Adial Pharmaceuticals, which may impact its stock trading and investor confidence. The company is required to respond to the notice and may need to take actions to maintain its Nasdaq listing.
- : Adial Pharmaceuticals acquires Azora Therapeutics
- : ADIAL PHARMACEUTICALS
- : ADIAL PHARMACEUTICALS
- : Adial Pharmaceuticals announces completion of the AD04 pharmacokinetics study results, aimed at treating Alcohol Use Disorder in patients with a specific genomic biomarker.
- : Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer
- : Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04
- : ADIAL PHARMACEUTICALS
Adial Pharmaceuticals funding history
| Date | Round | Amount |
|---|---|---|
| Dec 2025 | Venture | $4.3M |
| May 2025 | Venture | $4.8M |
| Mar 2024 | Seed | $288K |
| Oct 2023 | Seed | $4.0M |
| Jun 2023 | Pre-Seed | $53K |
Leadership
- William III, Executive Officer, Director
- James Anderson, Director
- Robertson Gilliland, Director
- James Jr., Director
- Kevin CFA, Director
- Tony Goodman, Director
- Cary Claiborne, Executive Officer, Director
- William III, Executive Officer, Director
- James Anderson, Director
- Robertson Gilliland, Director
- James Jr., Director
- Kevin Schuyler, Director
Verified email and direct lines for Adial Pharmaceuticals’s decision-makers are on Fundz. See plans
Employee benefit plans
Adial Pharmaceuticals files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Jul 2027.
Adial Pharmaceuticals in the news
- Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire (Sep 30, 2026)
- A new hire's right to buy 155,446 Adial shares vests over four years. - Stock Titan (Sep 30, 2026)
- AD04 Application Submitted to FDA Commissioner’s National Priority Voucher Pilot Program for Potential Expedited Review - Psychiatric Times (Apr 27, 2026)
- Adial Pharmaceuticals Acquires Azora Therapeutics and Secures Up to $64 Million Financing - citybiz (Jun 11, 2026)
- Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update - GlobeNewswire (Aug 17, 2026)
- A new Adial employee gets a 307,814-share option at $5.76 - Stock Titan (Aug 25, 2026)
- Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing - Yahoo Finance (Jun 16, 2026)
- Colon‑targeted ulcerative colitis drug draws up to $64M funding - Stock Titan (Jun 11, 2026)
Companies similar to Adial Pharmaceuticals
- Os Therapies · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Lipella Pharmaceuticals · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Galmed Pharmaceuticals Ltd · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- EyePoint Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- AIM ImmunoTech · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About Adial Pharmaceuticals: questions and answers
What does Adial Pharmaceuticals do?
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Comp
Where is Adial Pharmaceuticals headquartered?
Adial Pharmaceuticals is headquartered in Charlottesville, Virginia, United States.
How many employees does Adial Pharmaceuticals have?
Adial Pharmaceuticals has about 17 employees.
Has Adial Pharmaceuticals raised funding?
Yes. Fundz has recorded 5 funding events for Adial Pharmaceuticals. The most recent, $4.3M, was in Dec 2025.
What is the latest news on Adial Pharmaceuticals?
On Sep 17, 2026, SEC 8-K (5.02): On September 17, 2026, Adial Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders where significant changes were approved by the stockholders. These include Amendment No. 8 to the 2017 Equity Incentive Plan, increasing the shares available for issuance, the adoption of
Is Adial Pharmaceuticals a public company?
Yes. Adial Pharmaceuticals is publicly traded under the ticker ADIL.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy